Valuation: Arcus Biosciences, Inc.

Market Cap 3.76B 3.22B 3.01B 2.76B 5.18B 360B 5.24B 35.59B 13.88B 181B 14.11B 13.81B 598B P/E 2026 *
-8.25x
P/E 2027 * -8.19x
Enterprise Value 3.32B 2.84B 2.66B 2.43B 4.57B 317B 4.63B 31.42B 12.25B 159B 12.46B 12.19B 528B EV / Sales 2026 *
42.2x
EV / Sales 2027 * 70.2x
Free-Float
71.2%
Yield 2026 *
-
Yield 2027 * -
1 day+3.20%
1 week+3.49%
Current month+8.22%
1 month+3.49%
3 months+27.81%
6 months+61.84%
Current year+28.02%
1 week 28.92
Extreme 28.9233
31.28
1 month 26.19
Extreme 26.19
31.28
Current year 18.52
Extreme 18.515
31.74
1 year 10.07
Extreme 10.07
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 72 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Sell

Founder

-20,067 0.0160%
11/06/26 Free

Director

22,600 0.0180%
23/01/26 Free

Chief Financial Officer

157,000 0.1269%
Change 5-day change 1-year change 3-year change Capi.($)
+3.05%+3.49%+191.10%+60.82% 3.76B
+1.09%+5.26%+4.44%+26.03% 51.22B
-1.33%+2.67%+473.33%+600.20% 45.38B
+2.32%+8.73%+20.33%+92.64% 41.97B
+0.83%+9.11%+39.29%+20.47% 42.15B
-0.93%-4.80%+17.39%+46.60% 31.95B
+0.16%+2.74% - - 16.73B
+2.29%+8.22%+38.10%+154.52% 17.1B
+0.03%+3.41%+7.12%+35.49% 14.76B
+2.09%+6.12%+92.31%+47.92% 13.91B
Average +0.97%+3.10%+98.16%+120.52% 27.89B
Weighted average by Cap. +0.65%+3.12%+105.00%+148.26%

Financials

2026 *2027 *
Net sales 78.61M 67.34M 63M 57.67M 108M 7.52B 110M 744M 290M 3.78B 295M 289M 12.5B 52.08M 44.61M 41.74M 38.21M 71.71M 4.98B 72.65M 493M 192M 2.5B 196M 191M 8.28B
Net income -451M -386M -361M -331M -621M -43.15B -629M -4.27B -1.67B -21.68B -1.69B -1.66B -71.7B -451M -387M -362M -331M -621M -43.18B -630M -4.27B -1.67B -21.69B -1.69B -1.66B -71.74B
Net Debt -441M -377M -353M -323M -607M -42.16B -615M -4.17B -1.63B -21.18B -1.65B -1.62B -70.05B -102M -87.51M -81.88M -74.95M -141M -9.77B -143M -967M -377M -4.91B -384M -375M -16.24B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
21/08/26 $30.54 +3.46% 178,375
20/08/26 $29.52 -2.73% 1,546,249
19/08/26 $30.35 +2.85% 1,816,243
18/08/26 $29.51 -0.17% 896,392
17/08/26 $29.56 +0.27% 2,174,609
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
29.52USD
Average target price
38.33USD
Spread / Average Target
+29.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock